AWHONN PRACTICE ALERT

AWHONN Practice alerts provide a timely response to practice issues that may include but are not limited to variations in practice, supply chain demands, and inconsistent guidelines. Using current evidence-based literature, the practice alert will identify the issue and associated risks, recommendations, and benefits of strategies for nurses, and appropriate references to guide practitioners in a timely manner.

Date: January 28, 2024

Reason for Alert: Administration of Arexvy, the GSK RSV vaccine that is not FDA approved for pregnant persons, has been reported.

Potential risks of the stated issue: Patient safety due to lack of pregnancy indication and potential lack of prevention of RSV in newborns.

Recommendations for practice:

- **Pfizer RSV Vaccine (Absryvo)** is the only recommended RSV vaccine for pregnant patients from 32 through 36 weeks’ gestation.
- Include **“Pregnancy Indication-Pfizer RSV vaccine (Absryvo) only”** on prescriptions for pharmacies.
- Locate pharmacies that administer the Pfizer RSV vaccination (Absryvo) at the nearest location to the pregnant patient by using the following location finder resource: [pfizervax.com](http://pfizervax.com)
  
  D. Meaney-Delman (personal communication, December 19, 2023)

- The shelf life for Pfizer Abrysvo is **24 months with storage at standard refrigerator temperatures between 2-8 C.** This means that some vaccines can be stored and used next year, thus reducing the risk of wasting vaccines.

Benefits of recommendations: Increase patient safety and protection of RSV in pregnant patients and newborns.